Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 1.00 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MYD88 | Q99836 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424366 | 1.00 | KMO (1.00) | KMOTRPV4STAT3HTR6TP53 | |
| SCHEMBL422729 | 0.99 | KMO (0.98) | KMOTRPV4STAT3HTR6TP53 | |
| SCHEMBL425012 | 0.93 | KMO (0.87) | KMOSTAT3HTR6POLBMYD88 | |
| SCHEMBL428975 | 0.93 | KMO (0.87) | KMOSTAT3HTR6POLBMYD88 | |
| SCHEMBL425616 | 0.92 | KMO (0.85) | KMOSTAT3HTR6POLBMYD88 | |
| SCHEMBL429355 | 0.86 | KMO (1.00) | KMOSTAT3POLBPLAUALDH1A1 | |
| SCHEMBL10148194 | 0.86 | KMO (0.84) | KMOSTAT3HTR6POLBPLAU | |
| SCHEMBL17146455 | 0.85 | KMO (0.82) | KMOSTAT3POLBPLAUALDH1A1 | |
| SCHEMBL10148119 | 0.85 | KMO (0.74) | KMOTRPV4ALDH1A1MEN1MAPT | |
| SCHEMBL424487 | 0.84 | KMO (0.81) | KMOSTAT3POLBPLAUALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118105414-A | Application of lactobacillus gasseri JM6 in preparation of products for preventing or treating endometritis | 善恩康生物科技（苏州）有限公司 | 2024-05-31 | — | — | CN | claimed |
| CN-116789722-A | Preparation method of gamithromycin degradation impurity | 浙江国邦药业有限公司 | 2023-09-22 | — | — | CN | claimed |
| US-12616747-B2 | Stabilized beta-coronavirus antigens | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| US-12617820-B2 | Engineered coronavirus spike (s) protein and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-05-05 | — | — | US | disclosed |
| US-20250257102-A1 | PREFUSION-STABILIZED HMPV F PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-08-14 | — | — | US | disclosed |
| US-12304930-B2 | Prefusion-stabilized hMPV F proteins | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-05-20 | — | — | US | disclosed |
| CN-119838627-A | High-activity in-situ crystallization catalyst and preparation method and application thereof | 潍坊正轩稀土催化材料有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-114553189-B | Parallel equalization method based on FPGA | 杭州电子科技大学 | 2025-04-15 | — | — | CN | disclosed |
| CN-119819353-A | High-stability in-situ crystallization catalyst and preparation method and application thereof | 潍坊正轩稀土催化材料有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119060050-A | Benzimidazole compound and application thereof | 中国药科大学 | 2024-12-03 | — | — | CN | disclosed |
| US-20240376158-A1 | PREFUSION-STABILIZED HMPV F PROTEINS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-14 | — | — | US | disclosed |
| US-20230251973-A1 | FPGA-Based Parallel Equalization Method | HDU FUYANG ELECTRONIC INFORMATION RESEARCH INSTITUTE CO., LTD (CN) | 2023-08-10 | — | — | US | disclosed |
| US-20230242594-A1 | ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | US | disclosed |
| US-11559565-B2 | Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2023-01-24 | — | — | US | disclosed |
| CN-111880295-B | Variable magnification optical system and optical apparatus | 株式会社尼康 | 2022-12-09 | — | — | CN | disclosed |
| CN-114878703-A | Method for determining substance related to gamithromycin | 浙江国邦药业有限公司 | 2022-08-09 | — | — | CN | disclosed |
| CN-114561307-A | Yeast strain culture method with quorum sensing inhibition activity | 石河子大学 | 2022-05-31 | — | — | CN | disclosed |
| CN-114553189-A | Parallel equalization method based on FPGA | 杭州电子科技大学富阳电子信息研究院有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220153715-A1 | PURIFIED 2,5-FURANDICARBOXYLIC ACID PATHWAY PRODUCTS | STORA ENSO OYJ (FI) | 2022-05-19 | — | — | US | disclosed |
| CN-112745083-B | Barite weight-balance concrete and preparation method thereof | 青岛滨海建设天派砼业有限公司 | 2022-05-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220153715-A1 | PURIFIED 2,5-FURANDICARBOXYLIC ACID PATHWAY PRODUCTS | FDPS, HPD, FLAD1 | KMO 161/4885TRPV4 3462/4885STAT3 4649/4885 |
| US-12616747-B2 | Stabilized beta-coronavirus antigens | LY96, YWHAZ, SARS1 | KMO 4878/4885TRPV4 3122/4885STAT3 3155/4885 |
| US-12617820-B2 | Engineered coronavirus spike (s) protein and methods of use thereof | S100A8, S100A6, Q6ZSR9 | KMO 4865/4885TRPV4 3718/4885STAT3 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.